Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, now available in a 45 mg/0.5 mL single dose vial from Fresenius Kabi. 45 mg/0.5 mL single dose vial provides dosing flexibility for pediatric ...
Celltrion has obtained the Food and Drug Administration’s clearance for a new presentation of Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), in a 45mg/0.5ml solution in a ...
Patients may now switch between Stelara and Selarsdi, in all matching presentations, without prescriber intervention. The Food and Drug Administration (FDA) has approved Selarsdi ™ (ustekinumab-aken) ...
Patients may now switch between Otulfi and Stelara without requiring a prescription change from a health care provider. The Food and Drug Administration (FDA) has designated Otulfi ® (ustekinumab-aauz ...
INCHEON, South Korea, June 16, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA ® (ustekinumab-stba), a ...
Teva Pharmaceuticals and Alvotech announced that the Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection as interchangeable with Stelara (ustekinumab). As of April 30, 2025 ...
As the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, STELARA provides a new therapeutic option for children six years of age and older living with active psoriatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results